



## Cardiac Amyloidosis Study

The Henry Ford Heart & Vascular Institute is participating in a Cardiac Amyloidosis Study at Henry Ford Hospital, Detroit, MI.

Henry Ford Hospital is the only site in Michigan participating in a trial for identifying patients with TTR cardiac amyloidosis through free genetic testing for specific mutations.

When to consider cardiac amyloidosis:

1. Patients with heart failure and normal ejection fraction AND
2. Left ventricular hypertrophy
3. OR other associated conditions like atrial fibrillation, carpal tunnel syndrome or peripheral-neuropathy.

If genetic screen is positive your patient may qualify for subsequent participation in a randomized trial of a therapy (revusiran vs. placebo) for genetic variant of TTR cardiac amyloidosis (ENDEVOUR trial).

For more information regarding this trial to potentially help your patients with cardiac amyloidosis, please contact Karthik Ananth, M.D., FRCP(Glas), FACC, FASE, FASNC, Director, Nuclear Cardiology and Echocardiography Lab at (313) 916-4420 or Blake J. Vostrirancky, MS, ACSM-RCEP, Clinical Study Coordinator at (313) 492-0524.